Literature DB >> 8322039

Recent advances in the neuropathology of schizophrenia.

B Bogerts1.   

Abstract

This article reviews some 50 neuroanatomical postmortem studies published in the last 20 years. The majority of these studies demonstrated various types of subtle anomalies in limbic structures, that is, the hippocampus, parahippocampal gyrus, entorhinal cortex, amygdala, cingulate gyrus, and septum of schizophrenia patients. A number of schizophrenic symptoms might be related to structural and functional disturbances of these brain regions. But these studies also reported subtle changes in parts of the basal ganglia, thalamus, cortex, corpus callosum, and brainstem neurotransmitter systems. Many of the studies, however, are based on small sample sizes and, therefore, must be regarded as preliminary. Cytoarchitectonic abnormalities and lack of gliosis in limbic structures as well as the absence of normal structural cerebral asymmetry in a substantial proportion of patients indicate that these structural anomalies may reflect a disorder of prenatal brain development and argue against the notion that schizophrenia is a progressive degenerative brain disorder.

Entities:  

Mesh:

Year:  1993        PMID: 8322039     DOI: 10.1093/schbul/19.2.431

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  32 in total

1.  Subnucleus-specific loss of neurons in medial thalamus of schizophrenics.

Authors:  G J Popken; W E Bunney; S G Potkin; E G Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-01       Impact factor: 11.205

2.  Hippocampal pyramidal cell disarray correlates negatively to cell number: implications for the pathogenesis of schizophrenia.

Authors:  S A Jönsson; A Luts; N Guldberg-Kjaer; A Brun
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1997       Impact factor: 5.270

3.  AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodents.

Authors:  Mark D Black; Rachel J Stevens; Nancy Rogacki; Robert E Featherstone; Yaw Senyah; Odessa Giardino; Beth Borowsky; Jeanne Stemmelin; Caroline Cohen; Philippe Pichat; Michal Arad; Segev Barak; Amaya De Levie; Ina Weiner; Guy Griebel; Geoffrey B Varty
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

4.  The effect of laterality of stimulus presentation on auditory P300 topography in schizophrenia.

Authors:  F Bolsche; D J MacCrimmon; S Kropf
Journal:  J Psychiatry Neurosci       Date:  1996-03       Impact factor: 6.186

5.  Proteomics as a tool for understanding schizophrenia.

Authors:  Daniel Martins-de-Souza
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

6.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

7.  Expression of neurotrophins BDNF and NT-3, and their receptors in rat brain after administration of antipsychotic and psychotrophic agents.

Authors:  A M Lindén; J Väisänen; M Lakso; H Nawa; G Wong; E Castrén
Journal:  J Mol Neurosci       Date:  2000 Feb-Apr       Impact factor: 3.444

Review 8.  22q11 deletion syndrome: a genetic subtype of schizophrenia.

Authors:  A S Bassett; E W Chow
Journal:  Biol Psychiatry       Date:  1999-10-01       Impact factor: 13.382

9.  Neurodevelopmental theories of schizophernia : application to late-onset schizophernia.

Authors:  B W Palmer; D V Jeste
Journal:  Indian J Psychiatry       Date:  1996-01       Impact factor: 1.759

10.  Altered Thalamo-Cortical White Matter Connectivity: Probabilistic Tractography Study in Clinical-High Risk for Psychosis and First-Episode Psychosis.

Authors:  Kang Ik K Cho; Martha E Shenton; Marek Kubicki; Wi Hoon Jung; Tae Young Lee; Je-Yeon Yun; Sung Nyun Kim; Jun Soo Kwon
Journal:  Schizophr Bull       Date:  2015-11-23       Impact factor: 9.306

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.